GLP-1 drugs and hair loss: separating signal from noise

What did @realdrbae actually say?

The creator confirmed that GLP-1 medications can cause hair loss, naming it correctly as telogen effluvium, and described it as a speedup in the hair follicle cycle leading to faster shedding. They claimed some people may see "a 30 to 50% loss of hair density." They then pivoted to promoting a product called Hair Force One, describing it as "prescription grade" and "all natural" because it avoids finasteride and minoxidil, relying instead on biotin and vitamins.

The hair loss science portion was reasonably grounded. The product promotion portion is where things get slippery, and we need to separate those two conversations clearly.

Does the science back this up?

The telogen effluvium link to GLP-1 medications is real, though the mechanism is indirect. The hair loss appears to be driven by rapid caloric restriction and weight loss, not the drug itself, and that distinction matters clinically.

Clinical trials for semaglutide (SUSTAIN, STEP programs) listed alopecia as an adverse event in roughly 3% of participants, well below the dramatic framing of "30 to 50% loss of hair density." That density figure appears to describe the subjective experience of affected individuals, not a population-level finding. A 2023 review by Grover and Khurana in the Journal of Cosmetic Dermatology confirmed that telogen effluvium secondary to rapid weight loss is the most plausible driver, typically self-resolving within 3 to 6 months once weight stabilizes. The follicle cycle disruption the creator describes is accurate as far as the biology goes. Hair enters the telogen (resting) phase prematurely, and shedding follows 2 to 3 months later.

What did they get wrong (or right)?

The telogen effluvium explanation is largely correct, and credit is due for naming the condition and not catastrophizing it. The creator is right that most people around you will not notice it as much as you do, which tracks with how diffuse telogen effluvium presents.

The product promotion is a different story. Calling Hair Force One "prescription grade" while simultaneously calling it "all natural" is contradictory framing designed to make it sound both medically serious and free of risk. Biotin supplementation for hair loss has weak evidentiary support in people without a documented biotin deficiency. A 2017 review by Patel and colleagues in Skin Appendage Disorders found no controlled trials supporting biotin supplementation in non-deficient adults for hair growth. The claim that it "doesn't interact with other medications" is stated without qualification, which is an overreach. High-dose biotin is known to interfere with thyroid and cardiac lab assays, a fact the FDA flagged in 2017. That is not the same as a drug-drug interaction, but it is clinically relevant for GLP-1 patients who are often monitored closely.

What should you actually know?

If you are losing hair on a GLP-1 medication, the most evidence-backed intervention is adequate protein intake during weight loss, not a supplement stack. Telogen effluvium from caloric restriction responds to nutritional support, and most cases resolve without treatment.

The claim that avoiding finasteride and minoxidil makes Hair Force One safer deserves scrutiny. Finasteride and minoxidil are actually the two treatments with the strongest evidence base for androgenic alopecia. Minoxidil's blood pressure effect at topical doses used for hair loss is minimal and well-characterized. The suggestion that skipping proven treatments in favor of vitamins is the safer or smarter choice is not supported by dermatology guidelines. If hair loss is significant or not resolving, a dermatologist, not a TikTok-promoted supplement, is the right next step. The American Academy of Dermatology recommends evaluation for nutritional deficiencies including ferritin, zinc, and thyroid function before attributing hair loss to any single cause.

The bottom line

This video does a serviceable job explaining the biology of GLP-1-related hair loss and correctly identifies it as usually temporary. It earns less credit for the product promotion segment, which uses "prescription grade" as a credibility signal while leaning on ingredients with thin evidence. The framing of Hair Force One as safer because it avoids finasteride and minoxidil is backwards from what the literature supports. Hair loss during GLP-1 therapy is real, common enough to discuss, and usually manageable. A supplement with biotin and vitamins is not the primary answer, and presenting it as such without disclosing a commercial relationship is a pattern viewers should recognize.